Forside

Cell-o-matic annual report photo

CELL-O-MATIC

The CELL-O-MATIC Project has 13 partners from universities, industry and SME's and is headed by DTU Nanotech. The project has a total budget of 45 MDKK and is supported by the EU's 7th Frame Program.

The project ran for 4 years from 1 January 2012 - 31 December 2015. 

Contact

Anders Kristensen
Professor
DTU Nanotech
+45 45 25 63 31
Majken Lerche Møller
Project coordinator
DTU Nanotech
+45 45 25 67 37

FP7-logoEU flag

This project has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 278204.

 

mapDNA workshop

The Single Molecule DNA Mapping Workshop took place on 5 October 2015 at the Technical University of Denmark.

See the programme here

Project description

Cell-O-Matic: High Throughput Systematic Single Cell Genomics using Micro/Nano-Fluidic Chips for Extracting, Pre-analysing, Selecting and Preparing Sequence-ready DNA

The CELL-O-MATIC project will synergize efforts from SMEs, academics and large companies to develop a new chip-based technology for processing DNA from individual cells that will enhance the quality and throughput of present and future DNA sequencing significantly. This will open up for the next generation high-throughput sequencing. 

Especially in cancer management will single-cell analysis have many applications as DNA isolation and sequencing from tumour tissue and circulating tumour cells (CTC) has an important prognostic value.

A second innovation will be to develop methods that enable up to whole chromosome lengths of DNA to be contiguously mapped using nanofluidics. The inclusion of nanofluidics makes the project particularly distinctive and introduces European SMEs to an area that so far has been the domain of US companies.

The expected output of the project is the development of a modular prototype comprising a chip, fluid and thermal control, sonication and optical detection. Samples prepared using CELL-O-MATIC technology will be benchmarked in a high throughput environment with samples prepared by existing methods. Finally, the information obtained in the CELL-O-MATIC process about the sample material will be validated in a hospital for its direct utility in clinical decision making.

 Partners
 

University of Oxford

 

Roche Diagnostics GmbH

Genotype2Phenotype

Diagenode SA  Oxford Nanopore Limited  partner logo
Biocomputing platforms  Fasteris SA  DNA Electronics
     
http://www.cellomatic.eu/
31 JULY 2016